Like any successful business, we continue to evolve, progress, and achieve new goals. We would like to share these changes with you, so that you are always informed about the latest news.
Munich, 11th November 2019 – With a growth rate of 680 percent, the Munich-based company ADVITOS manages to reach 27th place in the Deloitte Technology Fast 50 2019.
With the Technology Fast 50 Award Deloitte annually honors the fastest-growing technology companies in the sectors of Hardware, Software, Communications, Media & Entertainment, Healthcare & Life Sciences, Environmental Technology and FinTech.
ADVITOS is the only listed MedTech company of the Technology Fast 50 Award and achieves the 27th place.
The ranking is based on the growth in sales over the last four financial years (2015 – 2018). ADVITOS was able to record a growth of 680 percent in this period. That was achieved with the commercialization of the inhouse-developed, CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device.
“We are very excited to be listed in the prestigious Deloitte Technology Fast 50 2019.”, says Assoc. Prof. Dr. med. Bernhard Kreymann, inventor of the ADVOS procedure, founder and CEO of ADVITOS GmbH. “It is a great recognition for the entire team who has worked very hard to make this happen. Further, this will give us visibility to investors and new customers which in turn will help us with further growth and the establishment of our innovative therapy in other markets.”
About ADVITOS – ADVITOS developed the CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device. ADVOS improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO2 (lungs). In addition, ADVOS enables treatment of acid-base disbalances through patient individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading university hospitals throughout Germany and is on its way to penetrating the international market.
Company’s ADVOS Technology Represents First System Worldwide for Advanced Multi-Organ Support
Munich, Germany, December 7, 2017 – Hepa Wash, a Munich-based manufacturer of the worldwide first
method for advanced multi-organ support, announced today its collaboration with the German Accelerator Life
Sciences (GALS) program, an initiative founded by the German Federal Ministry for Economic Affairs and Energy
(BMWi), to facilitate the company’s U.S. expansion.
The mortality rate of intensive care patients with multi-organ failure is still very high. Although dysfunctions of
the main detoxification organs, liver, lungs, and kidneys, can clearly be delineated, the failure of one organ can
affect several others. This leads to a life-threatening toxin accumulation in the body and subsequently to
progressive organ failure and death.
Hepa Wash recently introduced the innovative approach of the ADVOS (Advanced Organ Support) procedure,
which offers multi-organ support for liver, lungs, and kidneys and correction of acid-base balance disorders. The
ADVOS device represents an evolution from conventional dialysis machines, as it uses protein enriched dialysis
water instead of regular dialysis water and allows targeted manipulation of acidity of the dialysis fluid. Within
the device, the dialysis fluid is permanently reprocessed and cleared of toxins to maintain a constantly high
detoxification performance. The AVDOS procedure has already proven its capabilities in several studies and in
large university hospitals in Germany.
“We are very excited about being accepted into the GALS program. As this is a very competitive program, it
shows that our team has done great work so far. Also, highly accomplished US experts see the great potential of
our ADVOS multi-organ support to revolutionize treatment in intensive care settings and improve patient
survival,” commented Dr. Bernhard Kreymann, CEO and founder of Hepa Wash. “The U.S. market is the largest
medical technology market in the world, but it also follows its own set of rules. Therefore, it is of utmost
importance to be supported by experienced US specialists in establishing a strategy for market approval,
reimbursement, and market penetration. Hence, we very much look forward working with the GALS advisors to
analyze our US market readiness and develop our FDA and reimbursement strategy.”
“We look forward to working with Hepa Wash. The company’s ADVOS technology has enormous potential to
improve the treatment of organ-failure patients worldwide,” commented strategic project lead and GALS
mentor Michael Bogenstaetter. “I am confident that GALS can add to Hepa Wash’s success by assisting in the
continued development of the company’s U.S. strategy,” added Christoph Lengauer, CEO of the German
Accelerator Life Sciences.
Hepa Wash’s U.S. expansion will be guided by a team of GALS mentors with profound commercial and technical
expertise in the field of organ support. Additional support through GALS includes access to the vast GALS
network of medical device industry leaders, investors, and top-notch service providers.
About Hepa Wash:
Hepa Wash has established the ADVOS system, the first method in the world for extended and individualized support of the human body’s main detoxification organs: the liver, the lungs and the kidneys. The company was founded in Garching near Munich in mid-2005 by renowned nephrology and multi-organ support expert Dr. Bernhard Kreymann who had been instrumental in establishing the pervious gold standard of organ support using single-pass albumin dialysis. Building on this expertise, Hepa Wash is developing reliable treatment methods to close the therapeutic gap in multi-organ failure.
About the German Accelerator Life Sciences:
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi) with the goal of helping German startups and young companies succeed in the global marketplace. GALS, centrally located and highly connected in the world’s leading life sciences innovation hub in Cambridge, Massachusetts, offers support in multiple areas: from operational assistance to high-end strategic guidance by experienced industry experts and key opinion leaders. GALS opened its doors in October 2015 and is headquartered in Cambridge, Massachusetts.
For more information, visit: www.GermanAccelerator.com/Life-Sciences
Hepa Wash GmbH
Julia Rochser, M.A. Marketing Manager
+49 (89) 4111842-27
German Accelerator Life Sciences
Annika Pierson Head of Strategy & Operations
Additional Material: For more on the functionality of the ADVOS procedure, please click: http://hepawash.com/en/funktionsweise/PDF Download